ID   ES3
AC   CVCL_1199
SY   ES-3
DR   CLO; CLO_0009860
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1199
DR   Cell_Model_Passport; SIDM00265
DR   ChEMBL-Cells; CHEMBL3308150
DR   ChEMBL-Targets; CHEMBL2366135
DR   Cosmic; 684055
DR   Cosmic; 1995397
DR   Cosmic-CLP; 684055
DR   DepMap; ACH-002104
DR   EGA; EGAS00001000978
DR   GDSC; 684055
DR   GEO; GSM1669770
DR   GEO; GSM1676368
DR   GEO; GSM1701629
DR   IARC_TP53; 27155
DR   LINCS_LDP; LCL-1440
DR   PharmacoDB; ES3_339_2019
DR   PubChem_Cell_line; CVCL_1199
DR   Wikidata; Q54832636
RX   PubMed=20164919;
RX   PubMed=26351324;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236Ter (c.708C>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=1.17%; South Asian=1.4%; European, North=64.94%; European, South=32.49% (PubMed=30894373).
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 9
ST   D16S539: 12,13
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   TH01: 7,9.3
ST   TPOX: 8,12
ST   vWA: 14,20
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 30
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//